Skip to main content

Table 1 Clinical therapy details for the patient with relapse T-ALL

From: The evolution of malignant and reactive γδ + T cell clones in a relapse T-ALL case after allogeneic stem cell transplantation

Therapy date Therapy Response Blast cells (%) post-treatment CSF Intrathecal chemotherapy
BM / PB
18.11-01.12.2009 CTX, VCR, ADM, DXM PR 11 / 3 - MTX + DXM
18.12-22.12.2009 MTX, Ara-c , DXM NR 37 / 3   
25.01-30.01.2010 CTX, Ara-c, TPT NR 47 / 1 - Ara-c + DXM
05.03.2010 Allo-HSCT (conditioning regimen: Flu, BU/CY) CR 1 / 0 - MTX + DXM
13.04.2010 CsA, MP GVHD (Grade II) 0.5 / 0   
13.05.2010 CsA, MP GVHD under control 1.5 / 0 - MTX + DXM
12.08.2010- 07.01.2011 Radiotherapy CNSL cured 0 / 0 + (Ara-c + MTX + DXM) x 8 times
26.04-21.05.2012 VDS, NVT, L-ASPDXM Relapse, CR 3 / 0 - MTX + DXM (03.05 2012) Ara-c + DXM (25.05.2012)
08.06-06.07.2012 VCR, NVT, L-ASP, DXM, CTX CR 1 / 0 -  
  1. Notes: ADM adramycin, Ara-c cytarabine, BM bone marrow, BU busulfan, CNSL central nervous system leukemia, CsA cyclosporin, CSF cerebrospinal fluid,CTX cyclophosphamide, CR complete remission, CY cyclophosphamide, DXM dexamethasone, Flu fludarabine, L-ASP l-asparaginase, MP methylprednisolone,MTX Methotrexate, NR minor remission, NVT mitoxantrone, PR partial remission, PB peripheral blood, TPT Topotecan, VCR vincristine, VDS Vindesine.